Long-Term Response of Pembrolizumab in a Patient with Metastatic Squamous Non-Small Cell Lung Cancer on Hemodialysis: Case Report and Review of the Literature

Long-Term Response of Pembrolizumab in a Patient with Metastatic Squamous Non-Small Cell Lung Cancer on Hemodialysis: Case Report and Review of the Literature

In patients with renal failure and hemodialysis, there are difficulties in drug selection and dose adjustment for cancer treatment. The use of immune checkpoint inhibitors (ICIs), including pembrolizumab, approved by the U.S. Food and Drug Administration (FDA) for patients with metastatic non-small...

Full description

Bibliographic Details
Main Authors: Jae Won Yun, Jung Kwon, Taekyu Lim
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Medicina
Subjects:
pembrolizumab
hemodialysis
non-small cell lung cancer
end-stage renal disease
chronic kidney disease
Online Access:https://www.mdpi.com/1648-9144/59/2/325

Similar Items

Similar Items